NanoMedical Systems is an innovation company focused on bringing the precision and control of semiconductor engineering to the pharmaceutical development world to solve the bioanalytical challenges of today and of the future. Over a trillion dollars has been invested in the advancement of nanofabrication technologies for driving drug development, diagnostics and personalized medicine. NanoMedical Systems is launching its new product platform, the nHance™ Peptide Capture System (PCS). The nHance™ Peptide Capture System* is a revolutionary, patented nanotechnology developed specifically for peptide enrichment and quantification eliminating many of the cumbersome steps associated with other approaches. The nanoporous coating at the heart of this system absorbs peptides within its nanopores based on size-exclusion, electrical charge and hydrophobicity. However, unlike conventional sample preparation technologies on the market today, the peptides are first captured and then subsequently released after washing in a quick and seamless elution step for subsequent LC-MS analysis. It is truly a capture system for peptides and not a flow-through system based on retention time. As such, this approach allows sufficient time for both the size exclusion and electrostatic mechanisms of action to be fully utilized. Unwanted molecules and large debris are removed during the washing procedures. Peptides of interest are extracted for subsequent identification and quantification absent interference from the complex matrix. NanoMedical Systems is also working on another technology that is an implantable nanofluidics device for long-term, constant drug delivery of various drugs.